<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037149</url>
  </required_header>
  <id_info>
    <org_study_id>SRN-707-001</org_study_id>
    <nct_id>NCT05037149</nct_id>
  </id_info>
  <brief_title>Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors</brief_title>
  <official_title>Ph.1, Open-Label, Dose Escalation &amp; Expansion for Safety, Tolerability, PK, &amp; Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirnaomics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirnaomics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, dose escalation and dose expansion study to evaluate the safety, tolerability,&#xD;
      and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic&#xD;
      or surgically unresectable solid tumors who are refractory to standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1, open label, dose escalation and dose expansion study to evaluate the safety,&#xD;
      tolerability, and anti-tumor activity of STP707 with IV administration in subjects with&#xD;
      advanced/metastatic or surgically unresectable solid tumors who are refractory to standard&#xD;
      therapy.&#xD;
&#xD;
      The primary objective of this study is to determine the MTD or RP2D of STP707 and to&#xD;
      establish the dose of STP707 recommended for future phase 2 studies administered&#xD;
      intravenously.&#xD;
&#xD;
      A total of 30 subjects will be enrolled in dose escalation. Once MTD or RP2D has been&#xD;
      established, up to 10 additional subjects will enrolled to confirm safety and explore&#xD;
      anti-tumor activity.&#xD;
&#xD;
      Up to 5 dose levels will be explored (3,6,12,24,48 mg dose levels). Intermediate doses&#xD;
      between scheduled dose levels maybe explored during escalation. A cycle is 28 days.&#xD;
&#xD;
      Dose escalation will follow a standard 3+3 design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 design dose escalation followed by</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 Day Cycle</time_frame>
    <description>Recommended starting dose &amp; schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limited Dose Toxicity (LDT)</measure>
    <time_frame>28 day cycle</time_frame>
    <description>Recommended starting dose &amp; dose escalation</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP707</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Part 1: Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP707</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Part 1: Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP707</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Part 1: Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP707</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Part 1: Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP707</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Part 1: Arm E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with histologically or cytologically confirmed advanced / metastatic or&#xD;
             surgically unresectable solid tumors whose tumors are refractory to standard therapy&#xD;
&#xD;
          2. Measurable disease per RECIST v 1.1 (primary or metastatic disease)&#xD;
&#xD;
          3. ECOG performance status 0 - 1&#xD;
&#xD;
          4. Life expectancy of at least 3 months&#xD;
&#xD;
          5. Age ≥18 years&#xD;
&#xD;
          6. Signed, written Institutional Review Board (IRB) approved informed consent&#xD;
&#xD;
          7. A negative serum pregnancy test (for nonsterile women of child-bearing potential)&#xD;
&#xD;
          8. Acceptable liver function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) ≤ 5 times upper limit of normal because of cancer or&#xD;
                  metastases to the liver&#xD;
&#xD;
          9. Acceptable renal function, defined as:&#xD;
&#xD;
             o Serum creatinine ≤ 1.5 ULN or Creatinine Clearance ≥ 50 mL/minute&#xD;
&#xD;
         10. Acceptable hematologic status:&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (a transfusion is allowed if Hemoglobin stays stable&#xD;
                  thereafter)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000 plt/mm3 x 109/ L&#xD;
&#xD;
         11. Urinalysis with no clinically significant abnormalities&#xD;
&#xD;
         12. Acceptable coagulation status with partial thromboplastin time (PTT) and International&#xD;
             Normalized Ratio (INR) ≤ 1.5 times upper limit of normal unless patient is on&#xD;
             anticoagulants and has stable PTT and PT that are within normal therapeutic range for&#xD;
             disease under management&#xD;
&#xD;
         13. Subject has adequate vitamin D level, as defined by serum total 25-Hydroxyvitamin D&#xD;
             [25(OH)D] ≥ 20 to &lt; 60 ng/mL. If subjects are below this threshold, they may receive&#xD;
             vitamin D supplementation se per clinic dosing guidelines and may still be enrolled&#xD;
             provided they are started on vitamin D supplementation&#xD;
&#xD;
         14. Completion of all previous treatments (including surgery, systemic chemotherapy, and&#xD;
             radiotherapy) at least 3 weeks before screening&#xD;
&#xD;
         15. For men and women of child-producing potential, the use of effective contraceptive&#xD;
             methods during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Baseline Q-T corrected interval (QTc) interval of &gt; 470 msec for all subjects&#xD;
             calculated using Fridericia's formula&#xD;
&#xD;
          2. New York Heart Association Class III or IV cardiac disease, or myocardial infarction,&#xD;
             severe unstable angina, coronary/peripheral artery bypass graft, congestive heart&#xD;
             failure within the past 6 months&#xD;
&#xD;
          3. Known active, uncontrolled infection with HIV or hepatitis B; subjects with hepatitis&#xD;
             B allowed if on anti-viral therapy and have a viral load ≤ 500 IU; patients with a&#xD;
             history of HIV must be on antiretroviral therapy for at least four weeks and have an&#xD;
             HIV viral load ≤ 400 copies/mL, have CD4+ T cell counts ≥ 350 cells/uL and no history&#xD;
             of AIDS-defining opportunistic infections within 3 months prior to treatment&#xD;
&#xD;
          4. Major surgical procedure within 4 weeks prior to initiation of study treatment, or&#xD;
             anticipation of need for a major surgical procedure, during the course of the study.&#xD;
             (Note: Placement of a central venous access catheter(s) (e.g., port or similar) is not&#xD;
             considered a major surgical procedure.)&#xD;
&#xD;
          5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          6. Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree&#xD;
             to use adequate contraception (hormonal or barrier method of birth control; or&#xD;
             abstinence) prior to study entry and for the duration of study participation. Should a&#xD;
             woman become pregnant or suspect she is pregnant while participating in this study,&#xD;
             she should inform her treating physician immediately.&#xD;
&#xD;
          7. Participation in a clinical study involving administration of an investigational&#xD;
             compound within the past 30 days prior to study entry.&#xD;
&#xD;
          8. Unwillingness or inability to comply with procedures required in this protocol&#xD;
&#xD;
          9. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients in&#xD;
             the formulation (e.g., Trehalose dihydrate)&#xD;
&#xD;
         10. Existence of any surgical, medical or laboratory condition that, in the judgment of&#xD;
             the clinical investigator, might interfere with the safety, distribution, metabolism&#xD;
             or excretion of the drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nadia Sheibani</last_name>
    <phone>13057401730</phone>
    <email>nadiasheibani@sirnaomics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Sheibani</last_name>
    <email>nadiasheibani@sirnaomics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Gordon</last_name>
      <email>joshua.gordon@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Jason Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia DeLeaon</last_name>
      <phone>210-580-9521</phone>
      <email>cdeleon@nextoncology.com</email>
    </contact>
    <investigator>
      <last_name>Andrae Vandross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

